1-5 of 5
Remus Vezan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results

Clinical Trials & Observations
Bijal D. Shah, Michael R. Bishop, Olalekan O. Oluwole, Aaron C. Logan, Maria R. Baer, William B. Donnellan, Kristen M. O’Dwyer, Houston Holmes, Martha L. Arellano, Armin Ghobadi, John M. Pagel, Yi Lin, Ryan D. Cassaday, Jae H. Park, Mehrdad Abedi, Januario E. Castro, Daniel J. DeAngelo, Adriana K. Malone, Raya Mawad, Gary J. Schiller, John M. Rossi, Adrian Bot, Tong Shen, Lovely Goyal, Rajul K. Jain, Remus Vezan, William G. Wierda
Journal: Blood
Blood (2021) 138 (1): 11–22.
https://doi.org/10.1182/blood.2020009098
Published: 2021
Includes: Supplemental data
Journal Articles

Long-Term Survival and Gradual Recovery of B Cells in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel (Axi-Cel)

Caron Jacobson, MD MMSc, Frederick L. Locke, MD, Armin Ghobadi, MD, David B. Miklos, MD PhD, Lazaros J. Lekakis, MD, Olalekan O. Oluwole, MBBS, MPH, Yi Lin, MD PhD, Ira Braunschweig, MD, Brian T. Hill, MD, John M. Timmerman, MD, Abhinav Deol, MD, Patrick M. Reagan, MD, Patrick J. Stiff, MD, Ian W. Flinn, MD PhD, Umar Farooq, MD, Andre H. Goy, MD, Peter A. McSweeney, MD, Javier Munoz, MD, Tanya Siddiqi, MD, John M. Rossi, MS, Adrian Bot, MD PhD, Lianqing Zheng, PhD, Remus Vezan, MD PhD, Zahid Bashir, MBBS, Jenny J. Kim, MD MS, Rong Chu, PhD, Sattva S. Neelapu, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–42.
https://doi.org/10.1182/blood-2020-134362
Published: 2020
Journal Articles

Primary Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Caron Jacobson, MD MMSc, Julio C. Chavez, MD, Alison R. Sehgal, MD, Basem M. William, MDMRCP, Javier Munoz, MD, Gilles Salles, MDPhD, Pashna N. Munshi, MD, Carla Casulo, MD, David Maloney, MD PhD, Sven de Vos, MD PhD, Ran Reshef, MD, Lori A. Leslie, MD, Ibrahim Yakoub-Agha, Olalekan O. Oluwole, MBBS, MPH, Henry C.H. Fung, MD, Joseph D. Rosenblatt, MD, John M. Rossi, MS, Lovely Goyal, PhD, Vicki Plaks, LLB, PhD, Yin Yang, MS, Jennifer Lee, BS, Wayne Godfrey, MD, Remus Vezan, MD PhD, Mauro P. Avanzi, MD PhD, Sattva S. Neelapu, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–41.
https://doi.org/10.1182/blood-2020-136834
Published: 2020
Journal Articles

Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab

Clinical Trials & Observations
John C. Byrd, Peter Hillmen, Susan O’Brien, Jacqueline C. Barrientos, Nishitha M. Reddy, Steven Coutre, Constantine S. Tam, Stephen P. Mulligan, Ulrich Jaeger, Paul M. Barr, Richard R. Furman, Thomas J. Kipps, Patrick Thornton, Carol Moreno, Marco Montillo, John M. Pagel, Jan A. Burger, Jennifer A. Woyach, Sandra Dai, Remus Vezan, Danelle F. James, Jennifer R. Brown
Journal: Blood
Blood (2019) 133 (19): 2031–2042.
https://doi.org/10.1182/blood-2018-08-870238
Published: 2019
Includes: Supplemental data
Journal Articles

Updated Phase 1 Results of Zuma-3: Kte-C19, an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

William G. Wierda, MD PhD, Michael R. Bishop, MD, Olalekan O. Oluwole, MBBS, MPH, Aaron C. Logan, MD PhD, Maria R. Baer, MD, William B. Donnellan, MD, Kristen M. O'Dwyer, MD, Januario E. Castro, MD, Gary J. Schiller, MD, Houston Holmes, MD, Mehrdad Abedi, MD, Armin Ghobadi, MD, Martha L. Arellano, MD, Adriana K. Malone, MD, John M. Pagel, MD PhD, Armen Mardiros, PhD, Tong Shen, MS, Remus Vezan, MD PhD, Rajul K. Jain, MD, Bijal D. Shah, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 897.
https://doi.org/10.1182/blood-2018-99-111531
Published: 2018